Skip to main content
. 2020 Jul 30;12(8):713. doi: 10.3390/pharmaceutics12080713

Table 3.

Severity of potential drug–drug interactions (pDDIs; n = 928) among studied chronic kidney disease (CKD) patients.

Severity of pDDIs N %
Type A (No known interaction) 11 1.2
Type B (mild severity) 84 9.1
Type C (moderate severity) 717 77.3
Type D (major severity) 106 11.4
Type X (avoid drug combination) 10 1.1